TY - JOUR
T1 - Long-term outcomes among older patients with non-ST-segment elevation myocardial infarction complicated by cardiogenic shock
AU - Bagai, Akshay
AU - Chen, Anita Y.
AU - Wang, Tracy Y.
AU - Alexander, Karen P.
AU - Thomas, Laine
AU - Ohman, E. Magnus
AU - Hochman, Judith S.
AU - Peterson, Eric D.
AU - Roe, Matthew T.
N1 - Funding Information:
Dr Bagai, Ms Chen, Dr Alexander, and Dr Thomas, have no relevant disclosures to report. Dr Wang reports research funding from AstraZeneca; Bristol Myers Squibb; Gilead; Heartscape Technologies, Inc; Lilly; Sanofi-Aventis; Schering-Plough Corporation; and the Medicines Company (all significant). Dr Wang also reports consulting for the American College of Cardiology (significant), AstraZeneca (modest), and Medco (modest). All conflicts can be found at www.dcri.org . Dr Ohman reports research funding from Daiichi-Sankyo, Eli Lilly & Company, and Gilead Sciences (all significant). Dr Ohman also reports consulting for AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb; Lipscience; Merck; Pozen, Inc; Sanofi-Aventis; The Medicines Company (all modest); Gilead Sciences; Janssen Pharmaceuticals; and WebMD (all significant). All conflicts can be found at www.dcri.org . Dr Hochman reports consulting fees from Eli Lilly & Company and Glaxo Smith Kline. Dr Peterson reports research funding from Eli Lilly & Company; Ortho-McNeil-Janssen Pharmaceuticals, Inc; Society of Thoracic Surgeons; AHA; and American College of Cardiology (all significant). Dr Peterson also reports consulting for AstraZeneca; Boehringer Ingelheim; Genentech; Johnson & Johnson; Ortho-McNeil-Janssen Pharmaceuticals, Inc; Pfizer; Sanofi-Aventis; and WebMD (all modest). All conflicts can be found at www.dcri.org . Dr Roe reports research funding from Eli Lilly & Company, KAI Pharmaceuticals, and Sanofi-Aventis (all significant); educational activities for AstraZeneca and Janssen Pharmaceuticals (both modest); and consulting for Bristol Myers Squibb, Eli Lilly & Company, Glaxo Smith Kline, Regeneron (all modest), Merck & Co, Janssen Pharmaceuticals, and Daiichi-Sankyo (all significant). All conflicts can be found at www.dcri.org .
PY - 2013/8
Y1 - 2013/8
N2 - Background Cardiogenic shock complicating acute myocardial infarction (MI) in older patients is associated with a high risk of inhospital mortality; however, the long-term prognosis among these patients who survive the index hospitalization is uncertain. Methods We evaluated 42,656 patients 65 years or older with non-ST-segment elevation MI from the CRUSADE Registry treated at 448 hospitals in the United States from 2003 to 2006 and linked to Medicare longitudinal claims data. Among patients who survived to hospital discharge, Cox proportional hazards modeling was used to compare survival between patients with and without inhospital shock. The secondary outcome of "percent days alive and out of hospital" (%DAOH) was also compared between the 2 groups. Results Overall, 2,001 (4.7%) patients had shock on presentation and/or developed shock during the index hospitalization. Inhospital mortality rates among those with and without shock were 39.1% versus 4.5% (P <.001). Among the 40,036 index hospital survivors, postdischarge survival curves diverged early with lower survival (48.1% [95% CI 45.0-51.2] vs 56.5% [95% CI 56.0-57.1], P <.001) and lower %DAOH (65.5% ± 40.6% and 73.4% ± 36.8 %, P <.001) among patients with shock through 4 years. Based on the observation of parallel survival curves starting 6 months postdischarge, we performed landmark analyses and found no difference in mortality (hazard ratio 1.02, 95% CI 0.91-1.14) or %DAOH (79.7% ± 32.0% vs 81.3% ± 31.0%, P =.17) beyond 6 months between those with and without shock. Conclusions Our results highlight the time-dependent hazard of risk during the early postdischarge period for older patients with non-ST-segment elevation MI and cardiogenic shock that appears to be mitigated after 6 months, thereby lending support for the examination of new therapies designed to ameliorate this early risk.
AB - Background Cardiogenic shock complicating acute myocardial infarction (MI) in older patients is associated with a high risk of inhospital mortality; however, the long-term prognosis among these patients who survive the index hospitalization is uncertain. Methods We evaluated 42,656 patients 65 years or older with non-ST-segment elevation MI from the CRUSADE Registry treated at 448 hospitals in the United States from 2003 to 2006 and linked to Medicare longitudinal claims data. Among patients who survived to hospital discharge, Cox proportional hazards modeling was used to compare survival between patients with and without inhospital shock. The secondary outcome of "percent days alive and out of hospital" (%DAOH) was also compared between the 2 groups. Results Overall, 2,001 (4.7%) patients had shock on presentation and/or developed shock during the index hospitalization. Inhospital mortality rates among those with and without shock were 39.1% versus 4.5% (P <.001). Among the 40,036 index hospital survivors, postdischarge survival curves diverged early with lower survival (48.1% [95% CI 45.0-51.2] vs 56.5% [95% CI 56.0-57.1], P <.001) and lower %DAOH (65.5% ± 40.6% and 73.4% ± 36.8 %, P <.001) among patients with shock through 4 years. Based on the observation of parallel survival curves starting 6 months postdischarge, we performed landmark analyses and found no difference in mortality (hazard ratio 1.02, 95% CI 0.91-1.14) or %DAOH (79.7% ± 32.0% vs 81.3% ± 31.0%, P =.17) beyond 6 months between those with and without shock. Conclusions Our results highlight the time-dependent hazard of risk during the early postdischarge period for older patients with non-ST-segment elevation MI and cardiogenic shock that appears to be mitigated after 6 months, thereby lending support for the examination of new therapies designed to ameliorate this early risk.
UR - http://www.scopus.com/inward/record.url?scp=84880923388&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84880923388&partnerID=8YFLogxK
U2 - 10.1016/j.ahj.2013.05.003
DO - 10.1016/j.ahj.2013.05.003
M3 - Article
C2 - 23895813
AN - SCOPUS:84880923388
SN - 0002-8703
VL - 166
SP - 298
EP - 305
JO - American Heart Journal
JF - American Heart Journal
IS - 2
ER -